REFERENCES
- FDA approves testing of genes to personalize doses of drugs. Wall Street J 2005; 12, Jan[CSA]
- Kaplan A. Advances in pharmacogenomics reduce side effects and save lives. Psychiatr Times 2005; l22(1)4–7, [CSA]
- Kahn J. How a drug becomes “ethnic”: law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004; 4: 1–46, [PUBMED], [INFOTRIEVE], [CSA]
- Duster T. Medicine. Race and reification in science. Science 2005; 307: 1050–1, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Malhotra A K, Murphy G M, Jr, Kennedy J L. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780–96, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tate S K, Goldstein D B. Will tomorrow's medicines work for everyone?. Nat Genet 2004; l36(11 suppl)S34–42, [CROSSREF], [CSA]
- Melzer D, Raven A, Detmer D E, Ling T, Zimmern R L. My very own medicine: what I must know: information policy for pharmacogenetics. University of Cambridge, Cambridge 2003, http://www.phgu.org.uk/about_phgu/pharmacogenetics.html
- Basile V S, Masellis M, Potkin S G, Kennedy J L. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lin K M, Smith M W, Ortiz V. Culture and psychopharmacology. Psychiatr Clin North Am 2001; 24: 523–38, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Garrod A E. The incidence of alkaptonuria: a study in chemical individuality. Yale J Biol Med 2002; l75: 221–31, [originally published 1902][CSA]
- Bearn A G. Archibald Garrod and the individuality of man. Oxford University Press, New York 1993
- Lindee M S. Moments of truth in genetic medicine. Johns Hopkins University Press, Baltimore 2005
- Alving A S, Arnold J, Robinson D H, et al. Status of primaquine. JAMA 1952; 149: 1558–70, [CSA]
- Hughes H B, Biehl J P, Jones A P, Schmidt L H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954; 70: 266–73, [PUBMED], [INFOTRIEVE], [CSA]
- Evans D A, Manley K A, McKusick V A. Genetic control of isoniazid metabolism in man. Br Med J 1960; l5197: 485–91, [CSA]
- Dufour A P, Knight R A, Harris H W. Genetics of isoniazid metabolism in Caucasian, Negro, and Japanese populations. Science 1964; l145: 391, [CSA]
- Drayer D E, Reidenberg M M. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977; 22: 251–8, [PUBMED], [INFOTRIEVE], [CSA]
- Lehmann H, Ryan E. The familial incidence of low pseudocholinesterase level. Lancet 1956; l271: 124, [CROSSREF], [CSA]
- Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956; lii: 576–7, [CROSSREF], [CSA]
- Kalow W, Gunn D R. The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 1957; 120: 203–14, [PUBMED], [INFOTRIEVE], [CSA]
- Kalow W, Gunn D R. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 1959; 23: 239–50, [PUBMED], [INFOTRIEVE], [CSA]
- Kalow W. Pharmacogenetics: heredity and the response to drugs. Saunders, Philadelphia 1962
- Vogel F. Moderne Probleme der Humangenetik. Ergebnisse der inneren Medizin und Kinderheilkunde 1959; 12: 52–125, [CSA]
- Motulsky A G. Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc 1957; 165: 835–7, [PUBMED], [INFOTRIEVE], [CSA]
- Axelrod J. An unexpected life in research. Annu Rev Pharmacol Toxicol 1988; 28: 1–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Conney A H. Induction of drug-metabolizing enzymes: a path to the discovery of multiple cytochromes P450. Annu Rev Pharmacol Toxicol 2003; 43: 1–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vesell E S, Page J G. Genetic control of drug levels in man: antipyrine. Science 1968; 161: 72–3, [PUBMED], [INFOTRIEVE], [CSA]
- Vesell E S, Page J G. Genetic control of drug levels in man: phenylbutazone. Science 1968; 159: 1479–80, [PUBMED], [INFOTRIEVE], [CSA]
- Vesell E S. Intraspecies differences in frequency of genes directly affecting drug disposition: the individual factor in drug response. Pharmacol Rev 1978; 30: 555–63, [PUBMED], [INFOTRIEVE], [CSA]
- Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192–209, [PUBMED], [INFOTRIEVE], [CSA]
- Alvan G, Bertilsson L, Dahl M L, Ingelman-Sundberg M, Sjoqvist F. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metab Dispos 2001; l29(4)580–5, pt 2[CSA]
- Kalow W. Pharmacogenetics: past and future. Life Sci 1990; 47: 1385–97, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529–37, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wilkinson G R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211–21, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lin K M, Poland R E, Anderson D. Psychopharmacology, ethnicity, and culture. Transcultural Psychiatr Res 1995; 32: 3–40, [CSA]
- Kroemer H K, Eichelbaum M. “It's the genes, stupid”. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56: 2285–98, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bertilsson L, Lou Y Q, Du Y L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388–97, [PUBMED], [INFOTRIEVE], [CSA]
- Evans W E, McLeod H L. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538–49, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Aithal G P, Day C P, Kesteven P J, Daly A K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fellay J, Marzolini C, Meaden E R, et al. Response to antiretroviral treatment in HIV-1–infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Siddiqui A, Kerb R, Weale M E, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mancama D, Kerwin R W. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003; 17: 143–51, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang J H, Liu Z Q, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70: 42–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Meyer U A. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667–71, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621–4, [PUBMED], [INFOTRIEVE], [CSA]
- Caspi A, Sugden K, Moffitt T E, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508–11, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Benedetti F, Serretti A, Colombo C, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156: 1450–2, [PUBMED], [INFOTRIEVE], [CSA]
- Mundo E, Walker M, Cate T, Macciardi F, Kennedy J L. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001; 58: 539–44, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rousseva A, Henry C, van den Bulke D, et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J 2003; l3: 101–4, [CROSSREF], [CSA]
- Serretti A, Artioli P, Zanardi R, et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl) 2004; l174: 504–11, [CSA]
- Perlis R H, Mischoulon D, Smoller J W, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54: 879–83, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Serretti A, Lorenzi C, Lilli R, Smeraldi E. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 2000; 34: 89–98, [PUBMED], [INFOTRIEVE], [CSA]
- Steen V M, Lovlie R, Osher Y, Belmaker R H, Berle J O, Gulbrandsen A K. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8: 259–68, [PUBMED], [INFOTRIEVE], [CSA]
- Masui T, Hashimoto R, Kusumi I, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006; l9: 83–88, Epub 2005 June 1[CSA]
- Ebstein R, Horn-Saban S, Nemanov L, Shamir A, Belmaker R H, Agam G. Differential gene expression profiles due to lithium and bipolar disorder [Abstract]. Am J Med Genet 2000; l96: 482, [CSA]
- Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait?. J Clin Psychiatry 2002; 63: 942–7, [PUBMED], [INFOTRIEVE], [CSA]
- Lerer B. Understanding pharmacogenetics. Psychiatr Times 2003; l20(5)37–9, [CSA]
- Arranz M J, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Theisen F M, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005; 15: 285–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Reynolds G P, Zhang Z J, Zhang X B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Reynolds G P, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Murphy G M, Jr., Kremer C, Rodrigues H E, Schatzberg A F. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Murphy G M, Jr., Hollander S B, Rodrigues H E, Kremer C, Schatzberg A F. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Binder E B, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36: 1319–25, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shumyatsky G P, Malleret G, Shin R M, et al. Stathmin, a gene enriched in the amygdala, controls both learned and innate fear. Cell 2005; 123: 697–709, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tomita T, Iwatsubo T. The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease. Drug News Perspect 2004; 17: 321–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Espeseth A S, Xu M, Huang Q, et al. Compounds that bind APP and inhibit Aβ processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem 2005; 280: 17792–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Evans W E, Relling M V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–91, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roses A D. Reducing pipeline attrition in clinical development via pharmacogenetics. Drug Discov Devel 2003, August: 15, [CSA]
- Taylor A L, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–57, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Saul S. FDA approves a heart drug for African-Americans. NY Times 2005; 24, June[CSA]
- Koppal T. Designing personalized medicines. Drug Discov Devel 2003, April: 30–4, [CSA]
- Goldstein D B. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003; 348: 553–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bovet P, Paccaud F. Race and responsiveness to drugs for heart failure. N Engl J Med 2001; l345: 766, [CROSSREF], [CSA]
- Noah L. Pharmacogenetics. N Engl J Med 2003; l348: 2041–3, [CSA]
- Arranz M J, Munro J, Osborne S, Collier D, Kerwin R W. Difficulties in replication of results. Lancet 2000; 356: 1359–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirschhorn J N, Altshuler D. Once and again—issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002; 87: 4438–41, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Altshuler D, Brooks L D, Chakravarti A, Collins F S, Daly M J, Donnelly P. A haplotype map of the human genome. Nature 2005; 437: 1299–320, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004; 129: 36–40, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhang X, Beaulieu J M, Sotnikova T D, Gainetdinov R R, Caron M G. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004; l305: 217, [CROSSREF], [CSA]
- Zill P, Baghai T C, Zwanzger P, et al. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004; 9: 1030–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Padrini R, Ferrari M. Pharmacogenetics. N Engl J Med 2003; 348: 2041–3, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Xie H G, Kim R B, Wood A J, Stein C M. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Richardson H L, Stier A R, Borsos-Nachtnebel E. Liver tumor inhibition and adrenal histologic responses in rats to which 3′-methyl-4-dimethylaminoazobenzene and 20-methylcholanthrene were simultaneously administered. Cancer Res 1952; 12: 356–61, [PUBMED], [INFOTRIEVE], [CSA]
- Conney A H, Burns J J. Metabolic interactions among environmental chemicals and drugs. Science 1972; 178: 576–86, [PUBMED], [INFOTRIEVE], [CSA]
- Pantuck E J, Hsiao K C, Conney A H, et al. Effect of charcoal-broiled beef on phenacetin metabolism in man. Science 1976; 194: 1055–7, [PUBMED], [INFOTRIEVE], [CSA]
- Pantuck E J, Kuntzman R, Conney A H. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 1972; 175: 1248–50, [PUBMED], [INFOTRIEVE], [CSA]
- Conney A H, Pantuck E J, Hsiao K C, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976; 20: 633–42, [PUBMED], [INFOTRIEVE], [CSA]
- Alvares A P, Pantuck E J, Anderson K E, Kappas A, Conney A H. Regulation of drug metabolism in man by environmental factors. Drug Metab Rev 1979; 9: 185–205, [PUBMED], [INFOTRIEVE], [CSA]
- Derenne J L, Baldessarini R J. Clozapine toxicity associated with smoking cessation: case report. Am J Ther 2005; 12: 469–71, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Alvares A P, Kappas A, Eiseman J L, et al. Intraindividual variation in drug disposition. Clin Pharmacol Ther 1979; 26: 407–19, [PUBMED], [INFOTRIEVE], [CSA]
- Breen R, Thornhill J T. Noncompliance with medication for psychiatric disorders. CNS Drugs 1998; 9: 457–71, [CROSSREF], [CSA]
- Johnson R E, McFarland B H. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153: 993–1000, [PUBMED], [INFOTRIEVE], [CSA]
- Melartin T K, Rytsala H J, Leskela U S, Lestela-Mielonen P S, Sokero T P, Isometsa E T. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 2005; 66: 220–7, [PUBMED], [INFOTRIEVE], [CSA]
- Alving A S, Carson P E, Flanagan C L, Ickes C E. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124: 484–5, [PUBMED], [INFOTRIEVE], [CSA]
- Kalow W. Race and therapeutic drug response. N Engl J Med 1989; 320: 588–90, [PUBMED], [INFOTRIEVE], [CSA]
- Wood A J. Racial differences in the response to drugs—pointers to genetic differences. N Engl J Med 2001; 344: 1394–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383–4, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Freedman M L, Reich D, Penney K L, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004; 36: 388–93, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gelernter J, Kranzler H, Cubells J F. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997; 101: 243–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ruiz P, Varner R V, Small D R, Johnson B A. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q 1999; l70: 163–72, [CROSSREF], [CSA]
- Emsley R A, Roberts M C, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002; 63: 9–14, [PUBMED], [INFOTRIEVE], [CSA]
- Perlis R H, Sachs G S, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002; 159: 1155–9, [PUBMED], [INFOTRIEVE], [CSA]
- Kim D K, Lim S W, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–9, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miskimen T, Marin H, Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology (Berl) 2003; l171: 98–104, [CROSSREF], [CSA]
- Nakamura K, Goto F, Ray W A, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402–8, [PUBMED], [INFOTRIEVE], [CSA]
- Bonham V L, Warshauer-Baker E, Collins F S. Race and ethnicity in the genome era: the complexity of the constructs. Am Psychol 2005; 60: 9–15, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jones D S. Rationalizing epidemics: meanings and uses of American Indian mortality since 1600. Harvard University Press, Cambridge 2004
- Brandt A M. Racism and research: the case of the Tuskegee Syphilis Study. Hastings Cent Rep 1978; l8(6)21–9, [CSA]
- Walkup J T, McAlpine D D, Olfson M, Labay L E, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000; 61: 344–8, [PUBMED], [INFOTRIEVE], [CSA]
- Reardon J. Race to the finish: Identity and governance in an age of genomics. Princeton University Press, Princeton, NJ 2004
- Leroi A M. A family tree in every gene. NY Times 2005; l14: A23, March[CSA]
- Is race ‘real’?, [Social Science Research Council Web forum, 2005], http://raceandgenomics.ssrc.org, [CSA]
- Marks J. What it means to be 98% chimpanzee: apes, people, and their genes. University of California Press, Berkeley 2002
- Tishkoff S A, Kidd K K. Implications of biogeography of human populations for ‘race’ and medicine. Nat Genet 2004; l36(11 suppl)S21–7, [CROSSREF], [CSA]
- Jorde L B, Wooding S P. Genetic variation, classification and ‘race.’. Nat Genet 2004; l36(11 suppl)S28–33, [CROSSREF], [CSA]
- Rosenberg N A, Pritchard J K, Weber J L, et al. Genetic structure of human populations. Science 2002; 298: 2381–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mountain J L, Risch N. Assessing genetic contributions to phenotypic differences among ‘racial’ and ‘ethnic’ groups. Nat Genet 2004; l36(11 suppl)S48–53, [CROSSREF], [CSA]
- Tang H, Quertermous T, Rodriguez B, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005; 76: 268–75, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sinha M, Larkin E K, Elston R C, Redline S. Self-reported race and genetic admixture. N Engl J Med 2006; 354: 421–2, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- The International HapMap Project. Nature 2003; 426: 789–96, [CROSSREF], [CSA]
- Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; l38: 68–74, Epub 2005 Nov 10[CSA]
- Burchard E G, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003; 348: 1170–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McLeod H L. Pharmacogenetics: more than skin deep. Nat Genet 2001; 29: 247–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McLeod H L. Race and responsiveness to drugs for heart failure. N Engl J Med 2001; 345: 766–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Phimister E G. Medicine and the racial divide. N Engl J Med 2003; 348: 1081–2, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rotimi C N. Are medical and nonmedical uses of large-scale genomic markers conflating genetics and ‘race’?. Nat Genet 2004; l36(11 suppl)S43–7, [CROSSREF], [CSA]
- Parra E J, Kittles R A, Shriver M D. Implications of correlations between skin color and genetic ancestry for biomedical research. Nat Genet 2004; l36(11 suppl)S54–60, [CROSSREF], [CSA]
- Keita S O, Kittles R A, Royal C D, et al. Conceptualizing human variation. Nat Genet 2004; l36(11 suppl)S17–20, [CROSSREF], [CSA]
- Schwartz R S. Racial profiling in medical research. N Engl J Med 2001; 344: 1392–3, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Collins F S. What we do and don't know about ‘race’, ‘ethnicity’, genetics and health at the dawn of the genome era. Nat Genet 2004; l36(11 suppl)S13–5, [CROSSREF], [CSA]
- Cooper R S, Kaufman J S, Ward R. Race and genomics. N Engl J Med 2003; 348: 1166–70, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jones D S. The persistence of American Indian health disparities. Am J Public Health 2006, (in press)[CSA]
- Royal C D, Dunston G M. Changing the paradigm from ‘race’ to human genome variation. Nat Genet 2004; l36(11 suppl)S5–7, [CROSSREF], [CSA]
- The unexamined “Caucasian.”. Nat Genet 2004; l36: 541, [CROSSREF], [CSA]
- Zhou H H, Koshakji R P, Silberstein D J, Wilkinson G R, Wood A J. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320: 565–70, [PUBMED], [INFOTRIEVE], [CSA]
- Exner D V, Dries D L, Domanski M J, Cohn J N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yancy C W, Fowler M B, Colucci W S, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344: 1358–65, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wilson T W, Grim C E. Biohistory of slavery and blood pressure differences in blacks today. A hypothesis. Hypertension 1991; l17(1 suppl)I122–8, [CSA]
- Curtin P D. The slavery hypothesis for hypertension among African Americans: the historical evidence. Am J Public Health 1992; 82: 1681–6, [PUBMED], [INFOTRIEVE], [CSA]
- Sehgal A R. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004; l43: 566–72, [CROSSREF], [CSA]
- Wilson J F, Weale M E, Smith A C, et al. Population genetic structure of variable drug response. Nat Genet 2001; 29: 265–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002; l3, :comment2007.1–2007.12[CSA]
- Risch N. Dissecting racial and ethnic differences. N Engl J Med 2006; 354: 408–11, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Genes, drugs and race. Nat Genet 2001; 29: 239–40, [CROSSREF], [CSA]
- Bloche M G. Race-based therapeutics. N Engl J Med 2004; 351: 2035–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Isaacs S L, Schroeder S A. Class—the ignored determinant of the nation's health. N Engl J Med 2004; 351: 1137–42, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moyniham R. Report calls for better evaluation of pharmacogenetic tests. BMJ 2003; l327: 11, [CROSSREF], [CSA]
- Nierenberg A A, Feinstein A R. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA 1988; 259: 1699–702, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Marra C A, Esdaile J M, Anis A H. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507–12, [PUBMED], [INFOTRIEVE], [CSA]
- Perlis R H, Ganz D A, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005; 25: 427–34, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Warner J H. The therapeutic perspective: medical practice, knowledge, and identity in America, 1820–1885. Harvard University Press, Cambridge 1986
- Rosenberg C. The therapeutic revolution: medicine, meaning, and social change in nineteenth-century America. Explaining epidemics and other studies in the history of medicine. Cambridge University Press, Cambridge 1992; 9–31